The FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.
News|Articles|September 28, 2026
Q&A: Cutlip on the SELUTION SLR DEB’s FDA Approval for Coronary In-Stent Restenosis
Author(s)Donald Cutlip, MD
Fact checked by: Ryan Livingston
Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.
Advertisement
Advertisement
On September 21, 2026, the
Related to this article
Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.
Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study with more than 1000 participants with highly chronic TRD.
Kausik Ray, MD, MBChB, MPhil, discusses Lp(a)HORIZON, remnant cholesterol targets, enlicitide, and the lipid outcome trials to watch in 2027.
In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.
With LDL-C target-guided titration, starting statin plus ezetimibe vs a statin alone yielded similar 3-year events in ASCVD.
Stopping statins was noninferior at 2 years in adults 70 and older without CVD, but events were higher over full follow-up (12.7% vs 9.2%).
Advertisement
Advertisement